260 reports of this reaction
1.6% of all VASOPRESSIN reports
#13 most reported adverse reaction
HYPONATRAEMIA is the #13 most commonly reported adverse reaction for VASOPRESSIN, manufactured by Par Health USA, LLC. There are 260 FDA adverse event reports linking VASOPRESSIN to HYPONATRAEMIA. This represents approximately 1.6% of all 16,089 adverse event reports for this drug.
Patients taking VASOPRESSIN who experience hyponatraemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPONATRAEMIA is a less commonly reported adverse event for VASOPRESSIN, but still significant enough to appear in the safety profile.
In addition to hyponatraemia, the following adverse reactions have been reported for VASOPRESSIN:
The following drugs have also been linked to hyponatraemia in FDA adverse event reports:
HYPONATRAEMIA has been reported as an adverse event in 260 FDA reports for VASOPRESSIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPONATRAEMIA accounts for approximately 1.6% of all adverse event reports for VASOPRESSIN, making it a notable side effect.
If you experience hyponatraemia while taking VASOPRESSIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.